Key result
Carvedilol significantly reduced infarct size compared to controls after 30 minutes of coronary occlusion (8.7% vs 27.3%, P<.001) and reduced apoptosis independent of beta-blockade.
Why the study?
Does carvedilol or its analogue BM-91.0228 reduce infarct size and apoptosis in an experimental rat model of ischemia-reperfusion?
Population
Anesthetized rats subjected to an experimental infarct model
Comparison
Intravenous carvedilol or BM-91.0228… vs Control group
Design
Preclinical
Follow-up
30 minutes of reperfusion
Authors
Loading...
Carvedilol's infarct reduction in rats should not change clinical practice; leaves open translation of antiapoptotic effects to human ischemia-reperfusion injury.
Does carvedilol or its analogue BM-91.0228 reduce infarct size and apoptosis in an experimental rat model of ischemia-reperfusion?
Absolute Event Rate: 8.7% vs 27.3%
p-value: p=<.001
Carvedilol demonstrates cardioprotective effects by reducing ischemia-perfusion-induced necrosis and apoptosis in a rat model, with antiapoptotic effects appearing independent of beta-adrenoceptor blockade.
Schwarz et al. (2003) studied Experimental myocardial infarction. Carvedilol and BM-91.0228 vs. Control was evaluated on Infarct size after 30 minutes of coronary occlusion (p=<.001). Carvedilol significantly reduced infarct size compared to controls after 30 minutes of coronary occlusion (8.7% vs 27.3%, P<.001) and reduced apoptosis independent of beta-blockade.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: